VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
BRISBANE, Calif. - March 2, 2004 - VaxGen, Inc. (Nasdaq: VXGN) today announced results of its Phase I trial of recombinant Protective Antigen anthrax vaccine, rPA102, at the International Conference on Emerging Infectious Diseases (ICEID) in Atlanta, Georgia. The double-blind, multi-center study, which began in June 2003, was designed to examine the safety and immune response of a range of doses...Cell Genesys reports long term survival data in Phase II trial of GVAX prostate cancer vaccine
ORLANDO, FL, May 19, 2002Cell Genesys, Inc. (Nasdaq: CEGE) today reported encouraging long term survival data from a Phase II multicenter clinical trial of GVAX prostate cancer vaccine which demonstrates a dose-dependent trend toward prolonged survival in patients with hormone refractory prostate cancer metastatic to bone. In the 34-patient study, seven of 10 (70 percent) patients receiving the...Cell Genesys reports antitumor activity in Phase I/II GVAX lung cancer vaccine trial
.SAN FRANCISCO, Calif., May 13, 2001Cell Genesys, Inc. (Nasdaq: CEGE) today reported interim clinical data from its multicenter Phase I/II GVAX lung cancer vaccine trial which demonstrates objective evidence of antitumor activity including a major response rate of 18 percent in patients with advanced non small-cell lung cancer who have failed chemotherapy and/or radiation therapy. These data we.... . New Findings Suggest Improved Survival Even After Patient Relapse . Data Presented at the Annual Meeting of the American Society of Clinical Oncology . AVAX Technologies, Inc. (NASDAQ: AVXT) today announced the presentation of data at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO)(May 20-23) in New Orleans on the company's autologous cell vaccine (AC Vaccine.... . .Kansas City, MO, May 22, 2000 -- AVAX Technologies, Inc. (NASDAQ: AVXT) today announced the presentation of data at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO) (May 20-23) in New Orleans on the company's autologous cell vaccine (AC Vaccine™) O-Vax™, for ovarian cancer. The data gathered from an ongoing Phase 1/2 trial of O-Vax in patients with adva.... . . . Kansas City, MO, April 6, 2000 -- AVAX Technologies, Inc. (NASDAQ: AVXT) today announced that its Australian joint venture, AVAX Australia Pty. Ltd. has received an additional $3.0 million (AUD) investment from Neptunus International Holdings Limited (NIHL), which was recently renamed Australian Vaccine Technologies Ltd. (AVT). AVAX Australia holds the rights to manufacture and mark...AVAX Technologies' AC Vaccine™ improves relapse-free survival
. . . Kansas City, MO, April 5, 2000 -- AVAX Technologies, Inc. (NASDAQ: AVXT) today announced the presentation of preclinical data on its AC Vaccine™ technology, an autologous cell cancer vaccine, at the 91st Annual Meeting of the American Association for Cancer Research (AACR). The presentation outlined findings in a mouse model of breast cancer, indicating that vaccination with AVA...... ...... ... AVAX Technologies, Inc. (NASDAQ: AVXT) today announced the presentation of data at the 91st Annual Meeting of the American Association for Cancer Research (AACR), which indicate that M-Vax™, a cancer vaccine made from the patient's own tumor cells, induces T cell infiltration of metastatic sites. T cells are the class of white blood cells believed to be instrumental in fight...